Teva Shifts Strategy In Japan

Teva Takeda Divests To Nichi-Iko; Focuses On Complex Generics And Specialty

Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.

Japan
Teva has shifted its focus in Japan • Source: Shutterstock

Teva has announced a major strategic shift in Japan, involving plans to change the focus of its joint business venture with Takeda and divest a significant chunk of the unit’s generics business to Nichi-Iko.

“Nearly five years since its inception, and following an in-depth review of market opportunities,” Teva said, “the BV’s new strategy...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business